Quantification of T cell clonality in human T cell leukaemia virus type-1 carriers can detect the development of adult T cell leukaemia early Contributor Blood Cancer Behind the paper Quantification of T cell clonality in human T cell leukaemia virus type-1 carriers can detect the development of adult T cell leukaemia early +3 Aileen Rowan and 3 others Apr 08, 2021
HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemia Contributor Blood Cancer Behind the paper HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemia rmshaik Mar 30, 2021
Contributor Blood Cancer Behind the paper Successful treatment of relapse of PMBCL with CNS involvement. My diagnosis was PMBCL; stage IV Ruslana Mar 30, 2021
Contributor Blood Cancer Behind the paper Mutational landscape and its clinical significance in paroxysmal nocturnal hemoglobinuria Bing Han Mar 28, 2021
A new CAR-T therapy paradigm for treating B cell lymphomas Contributor Blood Cancer Behind the paper A new CAR-T therapy paradigm for treating B cell lymphomas Lung-Ji Chang Mar 27, 2021
Managing multiple myeloma in the modern era: getting the balance right for patients Contributor Blood Cancer Behind the paper Managing multiple myeloma in the modern era: getting the balance right for patients Evangelos Terpos Mar 26, 2021
Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up Contributor Blood Cancer Behind the paper Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up Elisabet E Manasanch Mar 17, 2021
Therapeutic outcome of early-phase clinical trials in multiple myeloma Contributor Blood Cancer Behind the paper Therapeutic outcome of early-phase clinical trials in multiple myeloma Niels van Nieuwenhuijzen Mar 17, 2021
All TP53 mutations are NOT equal: Does the "deleterious effect" of the TP53 mutation affect the outcome of Myelodysplastic Syndrome? Contributor Blood Cancer Behind the paper All TP53 mutations are NOT equal: Does the "deleterious effect" of the TP53 mutation affect the outcome of Myelodysplastic Syndrome? Rashmi Kanagal-Shamanna, MD Mar 10, 2021
Combating CLL Drug Resistance Contributor Blood Cancer Behind the paper Combating CLL Drug Resistance +1 Dr. Sutapa Sinha and 1 other Feb 24, 2021
Unveil mysterious “super-enhancers” in multiple myeloma Contributor Blood Cancer Behind the paper Unveil mysterious “super-enhancers” in multiple myeloma +1 Wee Joo Chng and 1 other Feb 18, 2021
Contributor Blood Cancer Behind the paper Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes Konstantinos Liapis & Ioannis Kotsianidis, on behalf of the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes. Konstantinos Liapis Feb 14, 2021
Mass spectrometry is a highly sensitive peripheral blood marker for measurable residual disease in multiple myeloma Contributor Blood Cancer Behind the paper Mass spectrometry is a highly sensitive peripheral blood marker for measurable residual disease in multiple myeloma +2 Ben Derman and 2 others Feb 11, 2021
Ruxolitinib discontinuation syndrome: incidence, risk factors and management in 251 patients with myelofibrosis Contributor Blood Cancer Behind the paper Ruxolitinib discontinuation syndrome: incidence, risk factors and management in 251 patients with myelofibrosis Francesca Palandri Jan 15, 2021
Understanding genomic factors contributing to disease progression in smoldering multiple myeloma Contributor Blood Cancer Nature Comms Behind the paper Understanding genomic factors contributing to disease progression in smoldering multiple myeloma Brian Walker Jan 12, 2021
Co-mutations, mutation order and clone size concur to determine disease phenotype of SRSF2-mutated neoplasms Contributor Blood Cancer Leukemia Nature Behind the paper Co-mutations, mutation order and clone size concur to determine disease phenotype of SRSF2-mutated neoplasms Gabriele Todisco Jan 11, 2021
Shining a spotlight on race & ethnicity in systemic AL amyloidosis Contributor Blood Cancer Behind the paper Shining a spotlight on race & ethnicity in systemic AL amyloidosis +1 Andrew Staron and 1 other Nov 10, 2020
SARS-Cov-2 infection increases mortality in multiple myeloma patients Contributor Blood Cancer Behind the paper, COVID-19 SARS-Cov-2 infection increases mortality in multiple myeloma patients +1 Joaquin Martinez-Lopez and 1 other Nov 07, 2020
Contributor Blood Cancer Behind the paper ASXL1 mutation confers poor prognosis in PMF patients with low, but not high JAK2V617F allele burden +1 Yu-Hung Wang and 1 other Oct 12, 2020
Single nucleotide variants in cytokine genes alter the susceptibility and aggressiveness for follicular lymphoma Contributor Blood Cancer Behind the paper Single nucleotide variants in cytokine genes alter the susceptibility and aggressiveness for follicular lymphoma Guilherme Rossi Assis-Mendonça Oct 07, 2020
